Collagen Peptide Supplement Boosts Natural GLP-1 Production and Improves Blood Sugar Control in Mice and Humans | Research

The takeaway

A specific collagen hydrolysate (H80) increased natural GLP-1 production by up to 860% in prediabetic mice and improved postprandial glucose tolerance in both mice and a small human proof-of-concept study.

860% increase in active GLP-1 in prediabetic mice
The collagen hydrolysate H80 nearly 10-fold increased circulating active GLP-1 levels in prediabetic mice — stimulating the body's own production of the same hormone that drugs like semaglutide mimic.

What the researchers found

The collagen hydrolysate H80 (Nextida GC) demonstrated GLP-1-mediated metabolic improvements:

**In mice:**

- Blood glucose response reduced by 25% in lean and 36% in prediabetic mice at 4 g/kg

- Plasma active GLP-1 increased by 217% in lean and 860% in prediabetic mice

- Gastric emptying slowed by 60% after 21 days of supplementation

- Plasma insulin increased by 166% after 35 days of supplementation

**In humans (proof of concept):**

- A 5 g oral dose of H80 reduced postprandial glucose response in healthy, normoglycemic, and prediabetic participants

The mechanism appears to work through stimulating natural GLP-1 secretion from intestinal L-cells, mimicking the physiological pathway that GLP-1 receptor agonist drugs target pharmacologically.

Why it matters

GLP-1 receptor agonists like semaglutide are expensive injectable drugs with supply constraints. If a simple oral collagen peptide supplement can meaningfully boost the body's own GLP-1 production and improve glucose tolerance, it could offer an accessible, affordable complement to pharmaceutical approaches — particularly for the hundreds of millions of people with prediabetes who might not yet qualify for prescription drugs but could benefit from improved glucose regulation.

How the study worked

Collagen hydrolysates were screened in vitro for GLP-1-stimulating ability. The best candidate (H80) was tested in lean normoglycemic mice (acute oral glucose challenge 45 minutes after dosing) and overweight prediabetic mice (6 weeks daily supplementation with acute challenges at days 21 and 34). Oral glucose tolerance, plasma insulin, GLP-1 levels, and gastric emptying were measured. A small human proof-of-concept study also evaluated postprandial glucose response at a 5 g dose.

What this study cannot tell us

The human proof-of-concept study is described as small, with no specific participant numbers or statistical details provided in the abstract. The mouse doses (4 g/kg) are very high relative to the human dose (5 g total), and it's unclear whether the effects at human-practical doses will be clinically meaningful long-term. The study was industry-sponsored (the product has a brand name, Nextida GC), which may introduce bias. Long-term safety and efficacy data are lacking.

How to read the evidence

The mouse data is robust with significant results across multiple metabolic endpoints, but the human data is from a small, preliminary proof-of-concept study. The product's commercial branding (Nextida GC) and industry involvement warrant caution about potential bias. Larger, independent human randomized controlled trials are needed to confirm efficacy.

When this study was published

Published in 2024, this is a very recent study at the frontier of food-derived peptide bioactivity research. The convergence of supplement science and GLP-1 pharmacology reflects growing interest in dietary approaches to metabolic health.

The bigger picture

This study bridges the supplement and pharmaceutical worlds by showing that specific food-derived peptides can engage the same GLP-1 pathway targeted by blockbuster drugs like semaglutide. The concept of using dietary peptides to stimulate endogenous incretin production has gained momentum as researchers seek more accessible alternatives to injectable GLP-1 drugs. If confirmed in larger human trials, collagen-derived GLP-1 stimulants could become a practical tool for prediabetes prevention.

Questions still open

Can the dramatic GLP-1 increases seen in mice (up to 860%) be replicated at practical doses in humans in a larger randomized trial?
How does the magnitude of GLP-1 stimulation from collagen peptides compare to pharmaceutical GLP-1 receptor agonists?
Could daily collagen hydrolysate supplementation prevent progression from prediabetes to type 2 diabetes in at-risk populations?

Common questions

How can collagen peptides boost GLP-1 like a drug?

Your gut naturally produces GLP-1 when special cells (L-cells) in the intestinal lining detect nutrients. Certain peptides — including specific fragments from broken-down collagen — appear to be particularly potent at triggering these L-cells to release GLP-1. This is the same hormone that drugs like semaglutide mimic, but instead of injecting a synthetic version, the collagen peptides stimulate your body to make more of its own GLP-1.

Could this collagen supplement replace GLP-1 drugs like semaglutide?

Very unlikely as a direct replacement — pharmaceutical GLP-1 drugs produce much larger and more sustained effects. But for people with prediabetes or mild glucose intolerance who don't need prescription medication, a collagen supplement that boosts natural GLP-1 could be a helpful dietary tool. Think of it as a complement to a healthy diet rather than a drug substitute. Much more human research is needed to confirm these preliminary findings.

Read the original research

A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in Healthy, Normoglycemic and Prediabetic Humans.

Food science & nutrition, 12(11), 9607-9620

View on PubMed ↗Publisher’s paper ↗

Citation

Grasset, Estelle; Briand, François; Virgilio, Nicolina; Schön, Christiane; Wilhelm, Manfred; Cudennec, Benoit; Ravallec, Rozenn; Aboubacar, Hairati; Vleminckx, Sara; Prawitt, Janne; Sulpice, Thierry; Gevaert, Elien. (2024). A Specific Collagen Hydrolysate Improves Postprandial Glucose Tolerance in Normoglycemic and Prediabetic Mice and in a First Proof of Concept Study in Healthy, Normoglycemic and Prediabetic Humans.. Food science & nutrition, 12(11), 9607-9620. https://doi.org/10.1002/fsn3.4538